Literature DB >> 2083146

Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat.

R L Fitzgerald1, R V Blanke, A Poklis.   

Abstract

Studies to characterize the pharmacokinetics of the enantiomers of MDMA were conducted in rats using the iliac arterial cannulation. Two routes of administration, intravenous and subcutaneous, were evaluated at two dose levels for each route [20 and 40 mg/kg (+/-)-MDMA for subcutaneous, 10 and 20 mg/kg (+/-)-MDMA for intravenous administrations]. The average half-life (+/- SD) for all dosing groups was 2.5 +/- 0.8 h for (-)-(R)-MDMA and 2.2 +/- 0.8 h for (+)-(S)-MDMA. The more rapid clearance of (+)-(S)-MDMA compared with (-)-(R)-MDMA is consistent with the area under the curve (AUC) data of the parent drug and its primary metabolite MDA. The mean (+/- SD) AUC S/R ratios of MDMA and MDA were 0.70 +/- 0.05 and 3.1 +/- 0.8, respectively. Following a 20 mg/kg dose of racemic MDMA iv the mean (+/- SD) of the percent dose excreted as (-)-(R)-MDMA, (+)-(S)-MDMA, (-)-(R)-MDA, and (+)-(S)-MDA were 20 +/- 10, 12 +/- 6, 3 +/- 1, and 6 +/- 2, respectively.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2083146     DOI: 10.1002/chir.530020409

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  7 in total

Review 1.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

Review 2.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

3.  The pharmacokinetics of racemic MDPV and its (R) and (S) enantiomers in female and male rats.

Authors:  Michael D Hambuchen; Howard P Hendrickson; Melinda G Gunnell; Samantha J McClenahan; Laura E Ewing; Dillon M Gibson; Michael D Berquist; S Michael Owens
Journal:  Drug Alcohol Depend       Date:  2017-08-08       Impact factor: 4.492

Review 4.  Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

5.  Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) and R(-) MDMA on actigraphy-based daytime activity and sleep parameters in rhesus monkeys.

Authors:  Laís F Berro; Hannah Shields; Melis Odabas-Geldiay; Barbara O Rothbaum; Monica L Andersen; Leonard L Howell
Journal:  Exp Clin Psychopharmacol       Date:  2018-06-25       Impact factor: 3.157

6.  Ethanol-MDMA interactions in rats: the importance of interval between repeated treatments in biobehavioral tolerance and sensitization to the combination.

Authors:  Sami Ben Hamida; Erin Plute; Sonia Bach; Christine Lazarus; Antoine Tracqui; Christian Kelche; Anne Pereira de Vasconcelos; Byron C Jones; Jean-Christophe Cassel
Journal:  Psychopharmacology (Berl)       Date:  2007-03-08       Impact factor: 4.415

Review 7.  Synthetic Aminoindanes: A Summary of Existing Knowledge.

Authors:  Nikola Pinterova; Rachel R Horsley; Tomas Palenicek
Journal:  Front Psychiatry       Date:  2017-11-17       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.